risk of edema, fractures, bladder cancer Non-Insulin Injectable Agents (assign Z79.85): GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide [dual GIP/GLP-1]): Cardiovascular and renal protective
Reference List Chang, C
Tirzepatide# Tirzepatide is a 39-amino acid synthetic peptide that activates both the GIP receptor (GIPR) and the GLP-1 receptor
This matters because it shows how researchers expand the endpoint set depending on population and protocol: weight endpoints remain central, while glycaemic endpoints are included when the population and study design require them
25 The dosing schedule was 1000 g daily for 7 days, then 1000 g once per week for 1 month, then 1 1000 g injection monthly for 6 months
Unlike other cells in the body, fat cells are particularly susceptible to cold-induced stress